Zoledronic acid (English Wikipedia)

Analysis of information sources in references of the Wikipedia article "Zoledronic acid" in English language version.

refsWebsite

Global rank English rank

19nih.gov

4^th place

15web.archive.org

1^st place

14doi.org

2^nd place

4drugs.com

399^th place

333^rd place

4europa.eu

68^th place

117^th place

4semanticscholar.org

11^th place

8^th place

3nps.org.au

low place

1fiercebiotech.com

low place

8,828^th place

1books.google.com

3^rd place

1handle.net

102^nd place

76^th place

1fda.gov

447^th place

338^th place

1medicines.org.uk

3,823^rd place

2,387^th place

1ulb.ac.be

low place

1osteoporosis.foundation

low place

1worldcat.org

5^th place

books.google.com

Fischer J, Ganellin CR (2006). Analogue-based Drug Discovery. John Wiley & Sons. p. 524. ISBN 9783527607495. Archived from the original on 14 January 2023. Retrieved 2 June 2020.

doi.org

Wardley A, Davidson N, Barrett-Lee P, Hong A, Mansi J, Dodwell D, et al. (May 2005). "Zoledronic acid significantly improves pain scores and quality of life in breast cancer patients with bone metastases: a randomised, crossover study of community vs hospital bisphosphonate administration". British Journal of Cancer. 92 (10): 1869–1876. doi:10.1038/sj.bjc.6602551. PMC 2361764. PMID 15870721.{{cite journal}}: CS1 maint: overridden setting (link)
Dhillon S (November 2016). "Zoledronic Acid (Reclast, Aclasta): A Review in Osteoporosis". Drugs. 76 (17): 1683–1697. doi:10.1007/s40265-016-0662-4. PMID 27864686. S2CID 22079489.
Lyles KW, Colón-Emeric CS, Magaziner JS, Adachi JD, Pieper CF, Mautalen C, et al. (November 2007). "Zoledronic acid and clinical fractures and mortality after hip fracture". The New England Journal of Medicine. 357 (18): 1799–1809. doi:10.1056/NEJMoa074941. PMC 2324066. PMID 17878149.{{cite journal}}: CS1 maint: overridden setting (link)
Black DM, Delmas PD, Eastell R, Reid IR, Boonen S, Cauley JA, et al. (May 2007). "Once-yearly zoledronic acid for treatment of postmenopausal osteoporosis". The New England Journal of Medicine. 356 (18): 1809–1822. doi:10.1056/nejmoa067312. PMID 17476007. S2CID 71443125.{{cite journal}}: CS1 maint: overridden setting (link)
Dwan K, Phillipi CA, Steiner RD, Basel D (October 2016). "Bisphosphonate therapy for osteogenesis imperfecta". The Cochrane Database of Systematic Reviews. 2016 (10): CD005088. doi:10.1002/14651858.CD005088.pub4. PMC 6611487. PMID 27760454.
Vondracek SF (April 2010). "Managing osteoporosis in postmenopausal women". American Journal of Health-System Pharmacy. 67 (7 Suppl 3): S9-19. doi:10.2146/ajhp100076. PMID 20332498.
Durie BG, Katz M, Crowley J (July 2005). "Osteonecrosis of the jaw and bisphosphonates" (PDF). The New England Journal of Medicine. 353 (1): 99–102, discussion 99–102. doi:10.1056/NEJM200507073530120. PMID 16000365. Archived (PDF) from the original on 21 August 2023. Retrieved 25 June 2023.
Koto K, Murata H, Kimura S, Horie N, Matsui T, Nishigaki Y, et al. (July 2010). "Zoledronic acid inhibits proliferation of human fibrosarcoma cells with induction of apoptosis, and shows combined effects with other anticancer agents". Oncology Reports. 24 (1): 233–239. doi:10.3892/or_00000851. PMID 20514467.{{cite journal}}: CS1 maint: overridden setting (link)
Reid IR, Brown JP, Burckhardt P, Horowitz Z, Richardson P, Trechsel U, et al. (February 2002). "Intravenous zoledronic acid in postmenopausal women with low bone mineral density". The New England Journal of Medicine. 346 (9): 653–661. doi:10.1056/NEJMoa011807. PMID 11870242.{{cite journal}}: CS1 maint: overridden setting (link)
Gnant M, Mlineritsch B, Schippinger W, Luschin-Ebengreuth G, Pöstlberger S, Menzel C, et al. (February 2009). "Endocrine therapy plus zoledronic acid in premenopausal breast cancer". The New England Journal of Medicine. 360 (7): 679–691. doi:10.1056/NEJMoa0806285. PMID 19213681.{{cite journal}}: CS1 maint: overridden setting (link)
Coleman RE, Winter MC, Cameron D, Bell R, Dodwell D, Keane MM, et al. (March 2010). "The effects of adding zoledronic acid to neoadjuvant chemotherapy on tumour response: exploratory evidence for direct anti-tumour activity in breast cancer". British Journal of Cancer. 102 (7): 1099–1105. doi:10.1038/sj.bjc.6605604. PMC 2853093. PMID 20234364.{{cite journal}}: CS1 maint: overridden setting (link)
Brufsky A, Bundred N, Coleman R, Lambert-Falls R, Mena R, Hadji P, et al. (May 2008). "Integrated analysis of zoledronic acid for prevention of aromatase inhibitor-associated bone loss in postmenopausal women with early breast cancer receiving adjuvant letrozole". The Oncologist. 13 (5): 503–514. doi:10.1634/theoncologist.2007-0206. PMID 18515735. S2CID 23710758.{{cite journal}}: CS1 maint: overridden setting (link)
Tonyali O, Arslan C, Altundag K (November 2010). "The role of zoledronic acid in the adjuvant treatment of breast cancer: current perspectives". Expert Opinion on Pharmacotherapy. 11 (16): 2715–2725. doi:10.1517/14656566.2010.523699. PMID 20977404. S2CID 26073229.
Delea TE, Taneja C, Sofrygin O, Kaura S, Gnant M (August 2010). "Cost-effectiveness of zoledronic acid plus endocrine therapy in premenopausal women with hormone-responsive early breast cancer". Clinical Breast Cancer. 10 (4): 267–274. doi:10.3816/CBC.2010.n.034. PMID 20705558.

drugs.com

"International trade names for zoledronic acid". Drugs.com. Archived from the original on 4 March 2016. Retrieved 14 January 2015.
"Zoledronic acid Use During Pregnancy". Drugs.com. 1 June 2020. Archived from the original on 16 November 2021. Retrieved 19 October 2020.
"Zoledronic Acid". The American Society of Health-System Pharmacists. Archived from the original on 15 December 2017. Retrieved 8 December 2017.
"FDA Alert: Reclast (zoledronic acid): Drug Safety Communication - New Contraindication and Updated Warning on Kidney Impairment". drugs.com. Archived from the original on 3 March 2016. Retrieved 23 January 2018.

europa.eu

ema.europa.eu

"Zometa EPAR". European Medicines Agency. 20 March 2001. Archived from the original on 7 June 2023. Retrieved 5 July 2024. Text was copied from this source which is copyright European Medicines Agency. Reproduction is authorized provided the source is acknowledged.
"Aclasta EPAR". European Medicines Agency (EMA). 15 April 2005. Retrieved 10 August 2024. Text was copied from this source which is copyright European Medicines Agency. Reproduction is authorized provided the source is acknowledged.
"European Medicines Agency - Human medicines". europa.eu. Archived from the original on 25 September 2015. Retrieved 3 April 2012.
"European Medicines Agency - Human medicines". europa.eu. Archived from the original on 19 January 2013. Retrieved 3 April 2012.

fda.gov

accessdata.fda.gov

"Zomera prescribing information" (PDF). Novartis Pharmaceuticals Corporation. U.S. Food and Drug Administration. April 2014. Archived (PDF) from the original on 19 June 2022. Retrieved 10 October 2023.

fiercebiotech.com

"Novartis's Reclast Receives FDA Approval for Women With Postmenopausal Osteoporosis". FierceBiotech (Press release). 20 August 2007. Archived from the original on 28 March 2018. Retrieved 2 September 2021.

handle.net

hdl.handle.net

World Health Organization (2023). The selection and use of essential medicines 2023: web annex A: World Health Organization model list of essential medicines: 23rd list (2023). Geneva: World Health Organization. hdl:10665/371090. WHO/MHP/HPS/EML/2023.02.

medicines.org.uk

emc.medicines.org.uk

"Zometa 4mg/5ml Concentrate for Solution for Infusion". medicines.org.uk. Archived from the original on 24 February 2010. Retrieved 24 February 2010.

nih.gov

pubmed.ncbi.nlm.nih.gov

Wardley A, Davidson N, Barrett-Lee P, Hong A, Mansi J, Dodwell D, et al. (May 2005). "Zoledronic acid significantly improves pain scores and quality of life in breast cancer patients with bone metastases: a randomised, crossover study of community vs hospital bisphosphonate administration". British Journal of Cancer. 92 (10): 1869–1876. doi:10.1038/sj.bjc.6602551. PMC 2361764. PMID 15870721.{{cite journal}}: CS1 maint: overridden setting (link)
Dhillon S (November 2016). "Zoledronic Acid (Reclast, Aclasta): A Review in Osteoporosis". Drugs. 76 (17): 1683–1697. doi:10.1007/s40265-016-0662-4. PMID 27864686. S2CID 22079489.
Lyles KW, Colón-Emeric CS, Magaziner JS, Adachi JD, Pieper CF, Mautalen C, et al. (November 2007). "Zoledronic acid and clinical fractures and mortality after hip fracture". The New England Journal of Medicine. 357 (18): 1799–1809. doi:10.1056/NEJMoa074941. PMC 2324066. PMID 17878149.{{cite journal}}: CS1 maint: overridden setting (link)
Black DM, Delmas PD, Eastell R, Reid IR, Boonen S, Cauley JA, et al. (May 2007). "Once-yearly zoledronic acid for treatment of postmenopausal osteoporosis". The New England Journal of Medicine. 356 (18): 1809–1822. doi:10.1056/nejmoa067312. PMID 17476007. S2CID 71443125.{{cite journal}}: CS1 maint: overridden setting (link)
Dwan K, Phillipi CA, Steiner RD, Basel D (October 2016). "Bisphosphonate therapy for osteogenesis imperfecta". The Cochrane Database of Systematic Reviews. 2016 (10): CD005088. doi:10.1002/14651858.CD005088.pub4. PMC 6611487. PMID 27760454.
Vondracek SF (April 2010). "Managing osteoporosis in postmenopausal women". American Journal of Health-System Pharmacy. 67 (7 Suppl 3): S9-19. doi:10.2146/ajhp100076. PMID 20332498.
Durie BG, Katz M, Crowley J (July 2005). "Osteonecrosis of the jaw and bisphosphonates" (PDF). The New England Journal of Medicine. 353 (1): 99–102, discussion 99–102. doi:10.1056/NEJM200507073530120. PMID 16000365. Archived (PDF) from the original on 21 August 2023. Retrieved 25 June 2023.
Koto K, Murata H, Kimura S, Horie N, Matsui T, Nishigaki Y, et al. (July 2010). "Zoledronic acid inhibits proliferation of human fibrosarcoma cells with induction of apoptosis, and shows combined effects with other anticancer agents". Oncology Reports. 24 (1): 233–239. doi:10.3892/or_00000851. PMID 20514467.{{cite journal}}: CS1 maint: overridden setting (link)
Reid IR, Brown JP, Burckhardt P, Horowitz Z, Richardson P, Trechsel U, et al. (February 2002). "Intravenous zoledronic acid in postmenopausal women with low bone mineral density". The New England Journal of Medicine. 346 (9): 653–661. doi:10.1056/NEJMoa011807. PMID 11870242.{{cite journal}}: CS1 maint: overridden setting (link)
Gnant M, Mlineritsch B, Schippinger W, Luschin-Ebengreuth G, Pöstlberger S, Menzel C, et al. (February 2009). "Endocrine therapy plus zoledronic acid in premenopausal breast cancer". The New England Journal of Medicine. 360 (7): 679–691. doi:10.1056/NEJMoa0806285. PMID 19213681.{{cite journal}}: CS1 maint: overridden setting (link)
Coleman RE, Winter MC, Cameron D, Bell R, Dodwell D, Keane MM, et al. (March 2010). "The effects of adding zoledronic acid to neoadjuvant chemotherapy on tumour response: exploratory evidence for direct anti-tumour activity in breast cancer". British Journal of Cancer. 102 (7): 1099–1105. doi:10.1038/sj.bjc.6605604. PMC 2853093. PMID 20234364.{{cite journal}}: CS1 maint: overridden setting (link)
Brufsky A, Bundred N, Coleman R, Lambert-Falls R, Mena R, Hadji P, et al. (May 2008). "Integrated analysis of zoledronic acid for prevention of aromatase inhibitor-associated bone loss in postmenopausal women with early breast cancer receiving adjuvant letrozole". The Oncologist. 13 (5): 503–514. doi:10.1634/theoncologist.2007-0206. PMID 18515735. S2CID 23710758.{{cite journal}}: CS1 maint: overridden setting (link)
Tonyali O, Arslan C, Altundag K (November 2010). "The role of zoledronic acid in the adjuvant treatment of breast cancer: current perspectives". Expert Opinion on Pharmacotherapy. 11 (16): 2715–2725. doi:10.1517/14656566.2010.523699. PMID 20977404. S2CID 26073229.
Delea TE, Taneja C, Sofrygin O, Kaura S, Gnant M (August 2010). "Cost-effectiveness of zoledronic acid plus endocrine therapy in premenopausal women with hormone-responsive early breast cancer". Clinical Breast Cancer. 10 (4): 267–274. doi:10.3816/CBC.2010.n.034. PMID 20705558.

ncbi.nlm.nih.gov

Wardley A, Davidson N, Barrett-Lee P, Hong A, Mansi J, Dodwell D, et al. (May 2005). "Zoledronic acid significantly improves pain scores and quality of life in breast cancer patients with bone metastases: a randomised, crossover study of community vs hospital bisphosphonate administration". British Journal of Cancer. 92 (10): 1869–1876. doi:10.1038/sj.bjc.6602551. PMC 2361764. PMID 15870721.{{cite journal}}: CS1 maint: overridden setting (link)
Lyles KW, Colón-Emeric CS, Magaziner JS, Adachi JD, Pieper CF, Mautalen C, et al. (November 2007). "Zoledronic acid and clinical fractures and mortality after hip fracture". The New England Journal of Medicine. 357 (18): 1799–1809. doi:10.1056/NEJMoa074941. PMC 2324066. PMID 17878149.{{cite journal}}: CS1 maint: overridden setting (link)
Dwan K, Phillipi CA, Steiner RD, Basel D (October 2016). "Bisphosphonate therapy for osteogenesis imperfecta". The Cochrane Database of Systematic Reviews. 2016 (10): CD005088. doi:10.1002/14651858.CD005088.pub4. PMC 6611487. PMID 27760454.
Coleman RE, Winter MC, Cameron D, Bell R, Dodwell D, Keane MM, et al. (March 2010). "The effects of adding zoledronic acid to neoadjuvant chemotherapy on tumour response: exploratory evidence for direct anti-tumour activity in breast cancer". British Journal of Cancer. 102 (7): 1099–1105. doi:10.1038/sj.bjc.6605604. PMC 2853093. PMID 20234364.{{cite journal}}: CS1 maint: overridden setting (link)

dailymed.nlm.nih.gov

"Reclast- zoledronic acid injection, solution". DailyMed. 7 July 2022. Retrieved 10 August 2024.

nps.org.au

National Prescribing Service (2009). "Zoledronic Acid for Osteoporosis". Medicines Update, Available at "Zoledronic acid (Aclasta) for osteoporosis: National Prescribing Service Ltd NPS". Archived from the original on 23 April 2010. Retrieved 20 January 2010.
"NPS MedicineWise" (PDF). Archived from the original (PDF) on 4 March 2016. Retrieved 25 January 2014.
"Aclasta label- Australia" (PDF). Archived from the original (PDF) on 4 March 2016. Retrieved 25 January 2014.

osteoporosis.foundation

"Bisphosphonates". International Osteoporosis Foundation. Retrieved 30 July 2022.^{[permanent dead link‍]}

semanticscholar.org

api.semanticscholar.org

Dhillon S (November 2016). "Zoledronic Acid (Reclast, Aclasta): A Review in Osteoporosis". Drugs. 76 (17): 1683–1697. doi:10.1007/s40265-016-0662-4. PMID 27864686. S2CID 22079489.
Black DM, Delmas PD, Eastell R, Reid IR, Boonen S, Cauley JA, et al. (May 2007). "Once-yearly zoledronic acid for treatment of postmenopausal osteoporosis". The New England Journal of Medicine. 356 (18): 1809–1822. doi:10.1056/nejmoa067312. PMID 17476007. S2CID 71443125.{{cite journal}}: CS1 maint: overridden setting (link)
Brufsky A, Bundred N, Coleman R, Lambert-Falls R, Mena R, Hadji P, et al. (May 2008). "Integrated analysis of zoledronic acid for prevention of aromatase inhibitor-associated bone loss in postmenopausal women with early breast cancer receiving adjuvant letrozole". The Oncologist. 13 (5): 503–514. doi:10.1634/theoncologist.2007-0206. PMID 18515735. S2CID 23710758.{{cite journal}}: CS1 maint: overridden setting (link)
Tonyali O, Arslan C, Altundag K (November 2010). "The role of zoledronic acid in the adjuvant treatment of breast cancer: current perspectives". Expert Opinion on Pharmacotherapy. 11 (16): 2715–2725. doi:10.1517/14656566.2010.523699. PMID 20977404. S2CID 26073229.

ulb.ac.be

dipot.ulb.ac.be

Durie BG, Katz M, Crowley J (July 2005). "Osteonecrosis of the jaw and bisphosphonates" (PDF). The New England Journal of Medicine. 353 (1): 99–102, discussion 99–102. doi:10.1056/NEJM200507073530120. PMID 16000365. Archived (PDF) from the original on 21 August 2023. Retrieved 25 June 2023.

web.archive.org

"International trade names for zoledronic acid". Drugs.com. Archived from the original on 4 March 2016. Retrieved 14 January 2015.
"Zoledronic acid Use During Pregnancy". Drugs.com. 1 June 2020. Archived from the original on 16 November 2021. Retrieved 19 October 2020.
"Zoledronic Acid". The American Society of Health-System Pharmacists. Archived from the original on 15 December 2017. Retrieved 8 December 2017.
"Zometa EPAR". European Medicines Agency. 20 March 2001. Archived from the original on 7 June 2023. Retrieved 5 July 2024. Text was copied from this source which is copyright European Medicines Agency. Reproduction is authorized provided the source is acknowledged.
"Novartis's Reclast Receives FDA Approval for Women With Postmenopausal Osteoporosis". FierceBiotech (Press release). 20 August 2007. Archived from the original on 28 March 2018. Retrieved 2 September 2021.
Fischer J, Ganellin CR (2006). Analogue-based Drug Discovery. John Wiley & Sons. p. 524. ISBN 9783527607495. Archived from the original on 14 January 2023. Retrieved 2 June 2020.
National Prescribing Service (2009). "Zoledronic Acid for Osteoporosis". Medicines Update, Available at "Zoledronic acid (Aclasta) for osteoporosis: National Prescribing Service Ltd NPS". Archived from the original on 23 April 2010. Retrieved 20 January 2010.
"Zomera prescribing information" (PDF). Novartis Pharmaceuticals Corporation. U.S. Food and Drug Administration. April 2014. Archived (PDF) from the original on 19 June 2022. Retrieved 10 October 2023.
"NPS MedicineWise" (PDF). Archived from the original (PDF) on 4 March 2016. Retrieved 25 January 2014.
"Zometa 4mg/5ml Concentrate for Solution for Infusion". medicines.org.uk. Archived from the original on 24 February 2010. Retrieved 24 February 2010.
"FDA Alert: Reclast (zoledronic acid): Drug Safety Communication - New Contraindication and Updated Warning on Kidney Impairment". drugs.com. Archived from the original on 3 March 2016. Retrieved 23 January 2018.
"European Medicines Agency - Human medicines". europa.eu. Archived from the original on 25 September 2015. Retrieved 3 April 2012.
Durie BG, Katz M, Crowley J (July 2005). "Osteonecrosis of the jaw and bisphosphonates" (PDF). The New England Journal of Medicine. 353 (1): 99–102, discussion 99–102. doi:10.1056/NEJM200507073530120. PMID 16000365. Archived (PDF) from the original on 21 August 2023. Retrieved 25 June 2023.
"European Medicines Agency - Human medicines". europa.eu. Archived from the original on 19 January 2013. Retrieved 3 April 2012.
"Aclasta label- Australia" (PDF). Archived from the original (PDF) on 4 March 2016. Retrieved 25 January 2014.

worldcat.org

search.worldcat.org

Tripathi KD (30 September 2013). Essentials of medical pharmacology (Seventh ed.). New Delhi: Jaypee Brothers Medical Publishers, Ltd. ISBN 9789350259375. OCLC 868299888.